FMO5 and diabetic kidney disease: Liu et al. [30] also found that TBHQ attenuates podocyte injury in diabetic nephropathy by inhibiting NADPH oxidase-derived ROS generation via the nuclear factor E2-related factor-2 /hemeoxygenase-1 signaling pathway.